Mubadala Capital

Tracked participation in 3 Atlas companies, with 3 explicitly attributed leads.

3portfolio companies

5round participations

3lead positions

$1.5Bled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Oct 2025CrusoeSeries E$1.4Bat $10B valuation Jun 2024Iambic TherapeuticsSeries B extension (oversubscribed)$50MJun 2023Iambic TherapeuticsSeries B Extension$50M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

WWaymoPhysical AIWaymo is Alphabet’s autonomous driving technology company, built to commercialize the Waymo Driver—a fully…$126Bvaluation$42.4BraisedRecent roundsInvestment round (growth financing) · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Oct 2024$5.6B · led by AlphabetWaymo$126BFeb 2026 → Feb 20262 roundsParticipant—

CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoe$10BOct 2025 → Oct 20251 round1 led—

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Jun 2023 → Jun 20242 rounds2 led—

DateCompanyRoundRaisedValuationRoleEvidence

Feb 02, 2026WWaymoPhysical AIWaymo is Alphabet’s autonomous driving technology company, built to commercialize the Waymo Driver—a fully…$126Bvaluation$42.4BraisedRecent roundsInvestment round (growth financing) · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Oct 2024$5.6B · led by AlphabetWaymoInvestment round (growth financing)$16B$126BParticipant

Source ↗

Feb 01, 2026WWaymoPhysical AIWaymo is Alphabet’s autonomous driving technology company, built to commercialize the Waymo Driver—a fully…$126Bvaluation$42.4BraisedRecent roundsInvestment round (growth financing) · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1investment round · Oct 2024$5.6B · led by AlphabetWaymoinvestment round$16B$126BParticipant

Source ↗

Oct 24, 2025CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoeSeries E$1.4B$10BLead

Source ↗

Jun 18, 2024ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B extension (oversubscribed)$50M—Lead

Source ↗

Jun 18, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B Extension$50M—Lead

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗